Centaurus Financial Inc. purchased a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,955 shares of the biotechnology company's stock, valued at approximately $2,778,000.
A number of other large investors also recently modified their holdings of AXON. Evergreen Capital Management LLC grew its holdings in shares of Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company's stock worth $342,000 after purchasing an additional 15 shares during the period. Synergy Financial Group LTD lifted its position in Axon Enterprise by 1.4% during the third quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company's stock valued at $996,000 after buying an additional 19 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Axon Enterprise by 1.2% during the second quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company's stock worth $1,350,000 after buying an additional 19 shares during the period. Certuity LLC grew its stake in Axon Enterprise by 5.1% during the fourth quarter. Certuity LLC now owns 474 shares of the biotechnology company's stock worth $269,000 after buying an additional 23 shares during the period. Finally, Pure Financial Advisors LLC increased its position in shares of Axon Enterprise by 6.7% in the fourth quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company's stock worth $207,000 after acquiring an additional 23 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on AXON. Royal Bank Of Canada restated an "outperform" rating on shares of Axon Enterprise in a report on Tuesday, July 21st. Morgan Stanley increased their price target on Axon Enterprise from $600.00 to $640.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. Barclays raised their price objective on Axon Enterprise from $523.00 to $688.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Needham & Company LLC reaffirmed a "buy" rating on shares of Axon Enterprise in a research report on Thursday, August 6th. Finally, Citizens Jmp reiterated a "market outperform" rating and issued a $700.00 target price on shares of Axon Enterprise in a research note on Thursday, June 25th. Thirteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $730.92.
Get Our Latest Report on AXON
Axon Enterprise Price Performance
Shares of AXON stock opened at $611.20 on Friday. The firm has a fifty day simple moving average of $557.20 and a 200-day simple moving average of $482.16. The company has a market capitalization of $49.65 billion, a PE ratio of 253.61, a price-to-earnings-growth ratio of 9.86 and a beta of 1.39. Axon Enterprise, Inc has a twelve month low of $339.01 and a twelve month high of $794.29. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The firm had revenue of $904.39 million for the quarter, compared to the consensus estimate of $876.42 million. During the same quarter in the previous year, the firm posted $2.12 EPS. The firm's quarterly revenue was up 35.3% on a year-over-year basis. Equities research analysts anticipate that Axon Enterprise, Inc will post 2.04 earnings per share for the current fiscal year.
Insider Activity at Axon Enterprise
In other news, CRO Cameron Brooks sold 1,242 shares of Axon Enterprise stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $500.00, for a total transaction of $621,000.00. Following the sale, the executive directly owned 49,710 shares of the company's stock, valued at approximately $24,855,000. The trade was a 2.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 13,000 shares of the business's stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $488.45, for a total value of $6,349,850.00. Following the completion of the transaction, the president owned 169,125 shares in the company, valued at approximately $82,609,106.25. This trade represents a 7.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 76,594 shares of company stock valued at $41,236,386. 4.20% of the stock is currently owned by insiders.
About Axon Enterprise
(
Free Report)
Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.
Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.
See Also
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Axon Enterprise, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axon Enterprise wasn't on the list.
While Axon Enterprise currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
